OR WAIT null SECS
March 31, 2025
Video
Ragni discussed unique advantages fitusiran offers over other approved therapies for hemophilia A or B.
March 30, 2025
Article
Pulse oximeter bias was less negative in darkly pigmented skin, suggesting a difference in performance across skin pigment categories.
Intravenous iron supplementation was safe but showed mixed improvement in cardiovascular outcomes in the FAIR-HF2 trial at ACC.25.
March 28, 2025
Data from the phase 3 ATLAS trial supported Qfitlia's BLA, with the latest data presented at December’s ASH meeting.
March 27, 2025
The AI-powered trial was officially initiated in January 2025.
Sidonio discussed how fitusiran may improve the treatment landscape and reduce treatment burden for people with hemophilia A or B with or without inhibitors.
March 26, 2025
Results suggest that post-operation intravenous iron therapy could both prevent anemia and offset logistical issues of identifying iron deficiency.
March 25, 2025
March 24, 2025
FCM yielded a statistically significant improvement in Hb levels in patients with postpartum anemia over IS.
March 20, 2025
A new systematic review finds IV iron effective for iron non-responders but calls for further studies on the causes of oral iron failure.